Form 4: Q32 Bio Inc. Director Isaac Manke Receives Stock Options in Lieu of Cash Compensation

Director Isaac Manke of Q32 Bio Inc. receives stock options in lieu of cash compensation for serving as a non-employee director.

Summary

• On April 1, 2024, Isaac Manke, a director of Q32 Bio Inc., was granted stock options to purchase 2,627 shares of common stock at an exercise price of $18.
• The options were granted in accordance with the Issuer's Non-Employee Director Compensation Policy, as Manke elected to receive equity in lieu of cash compensation.
• The shares underlying the option vest in three equal quarterly installments on June 30, 2024, September 30, 2024, and December 31, 2024.
• Following the transaction, Manke directly owns 2,627 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options to a director is a common practice and suggests alignment of interests with shareholders. The director choosing equity over cash also indicates confidence in the company.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• Electing to receive equity instead of cash compensation demonstrates confidence in the company's future performance.

Industry Context

Granting stock options to directors is a common practice in the biotech industry to align their interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a standard practice across various industries, particularly in high-growth sectors like biotechnology.
• The size of the grant (2,627 shares) and the vesting schedule (three equal quarterly installments) appear to be within typical ranges for director compensation packages in comparable companies.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their director compensation plans.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• The director benefits from potential gains in the company's stock price.

Key Dates